# Outcomes of Aquablation in BPH with bladder stones: Analysis of the ICARUS database

**Authors:** Joshua D. Cabral, Margaret Gannon, Gregory Raster, David J. Nusbaum, David Bouhadana, Adel Arezki, Aalya Hamouda, Anouk Leathead, Ilan Ohana, Rosie Foucault, Iman Sadri, Jeffrey A. Sioufi, Nick Lee, Tarek Benzouak, Liam Murad, Nicholas J. Corsi, John Klein, Inderjit Singh, James Kearns, Cecilia Chang, Juan Justo Quintas, Kevin C. Zorn, Tiago Rodrigues, Shawn H. Marhamati, Brian T. Helfand, Alexander P. Glaser

PMC · DOI: 10.1002/bco2.70156 · BJUI Compass · 2026-01-30

## TL;DR

This study shows that Aquablation effectively treats enlarged prostate in men with or without bladder stones, with similar outcomes.

## Contribution

The study is the first to analyze Aquablation outcomes in BPH patients with bladder stones using a large international cohort.

## Key findings

- Patients with bladder stones had longer operative times but no increased complications.
- Functional outcomes like IPSS, Qmax, and PVR improved similarly in both groups.
- Bladder stone patients had higher rates of prior BPH surgery and larger prostate volumes.

## Abstract

The purpose of this study is investigate the clinical outcomes of men with benign prostatic hyperplasia (BPH) and bladder stones treated concomitantly with Aquablation and bladder stone removal in an international, multi‐institutional cohort.

We performed a retrospective analysis of men who underwent Aquablation between 2018 and 2024. Patients were divided into two cohorts: men with bladder stones and those without. Outcomes assessed included baseline demographics and variables (medication use, prostate volume, prior BPH surgery), operative characteristics (OR time, transfusion requirement, complications), and functional outcomes were measured by the International Prostate Symptom Score (IPSS), peak urinary flow rate (Q
max) and PVR at regular intervals over 24 months.

A total of 1885 men were analysed, including 60 men with bladder stones and 1825 without. Patients with bladder stones had higher rates of prior BPH surgery (15% vs. 5.5%, p = 0.015) and pre‐operative urinary retention (28.3% vs. 14.8%, p = 0.004) as well as larger prostate volumes (98.6 ml vs. 77 ml, p < 0.0001). Total operative time was longer in the bladder stone group (76.5 mins vs. 55.0 mins, p < 0.001), but there were no significant differences in Aquablation time or bleeding complications including transfusions. There was also no difference in improvements in IPSS, Q
max and PVR post‐operatively.

This study demonstrates that Aquablation is safe and effective in the management of BPH regardless of concomitant bladder stone treatment.

## Linked entities

- **Diseases:** benign prostatic hyperplasia (MONDO:0010811)

## Full-text entities

- **Diseases:** urinary retention (MESH:D016055), bleeding (MESH:D006470), Symptom (MESH:D012816), bladder stone (MESH:D001744), Prostate (MESH:D011472), BPH (MESH:D011470)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12856958/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12856958/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC12856958/full.md

---
Source: https://tomesphere.com/paper/PMC12856958